[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA05008347A - Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis. - Google Patents

Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.

Info

Publication number
MXPA05008347A
MXPA05008347A MXPA05008347A MXPA05008347A MXPA05008347A MX PA05008347 A MXPA05008347 A MX PA05008347A MX PA05008347 A MXPA05008347 A MX PA05008347A MX PA05008347 A MXPA05008347 A MX PA05008347A MX PA05008347 A MXPA05008347 A MX PA05008347A
Authority
MX
Mexico
Prior art keywords
combination
oestrogen
progestin
endometriosis
compositon
Prior art date
Application number
MXPA05008347A
Other languages
English (en)
Inventor
Rubin Stephen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05008347A publication Critical patent/MXPA05008347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un metodo para el tratamiento de endometriosis, que utiliza una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno. La invencion tambien se refiere a formulaciones farmaceuticas que comprenden dicha combinacion.
MXPA05008347A 2003-02-05 2004-02-03 Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis. MXPA05008347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
MXPA05008347A true MXPA05008347A (es) 2005-11-04

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008347A MXPA05008347A (es) 2003-02-05 2004-02-03 Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.

Country Status (30)

Country Link
US (2) US7910570B2 (es)
EP (2) EP1857111A3 (es)
JP (2) JP4658918B2 (es)
KR (1) KR101075929B1 (es)
CN (1) CN100393360C (es)
AR (1) AR043013A1 (es)
AT (1) ATE374612T1 (es)
AU (1) AU2004210184B2 (es)
BR (1) BRPI0407039A (es)
CA (1) CA2513910C (es)
CO (1) CO5580789A2 (es)
CY (1) CY1107816T1 (es)
DE (1) DE602004009288T2 (es)
DK (1) DK1589976T3 (es)
ES (1) ES2293215T3 (es)
GB (1) GB0302572D0 (es)
HK (1) HK1082918A1 (es)
IL (1) IL169583A0 (es)
IS (1) IS2547B (es)
MX (1) MXPA05008347A (es)
MY (1) MY140723A (es)
NO (1) NO20053626L (es)
NZ (1) NZ541222A (es)
PL (1) PL214680B1 (es)
PT (1) PT1589976E (es)
RU (2) RU2360681C2 (es)
TW (1) TWI354556B (es)
UA (1) UA80741C2 (es)
WO (1) WO2004069260A1 (es)
ZA (1) ZA200506221B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US8871750B2 (en) * 2004-10-04 2014-10-28 Wayne State University Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
HUP0102483A3 (en) 1998-06-11 2002-11-28 Endorech Inc Sainte Foy Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
WO2002030355A2 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
DK1377298T3 (da) 2001-01-26 2007-01-02 Pfizer Italia Srl Exemestan til behandling af hormon-afhængige lidelser
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
AU2002342163B2 (en) 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
IL162769A0 (en) 2002-01-22 2005-11-20 Akzo Nobel Nv Tibolone in the treatment of complaints associatedwith the administration of drugs which prevent thesynthesis of endogenousestrogen
WO2003082254A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
AU2003213956A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Improved hormone replacement therapy
AU2003213958A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
CA2490533A1 (en) * 2002-06-27 2004-01-08 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
US20060142256A1 (en) 2006-06-29
CO5580789A2 (es) 2005-11-30
ES2293215T3 (es) 2008-03-16
HK1082918A1 (en) 2006-06-23
EP1857111A2 (en) 2007-11-21
UA80741C2 (en) 2007-10-25
IL169583A0 (en) 2007-07-04
AR043013A1 (es) 2005-07-13
CY1107816T1 (el) 2013-06-19
MY140723A (en) 2010-01-15
WO2004069260A1 (en) 2004-08-19
NZ541222A (en) 2008-12-24
CA2513910A1 (en) 2004-08-19
KR20050098296A (ko) 2005-10-11
JP4658918B2 (ja) 2011-03-23
PL377939A1 (pl) 2006-02-20
AU2004210184B2 (en) 2007-01-04
AU2004210184A1 (en) 2004-08-19
GB0302572D0 (en) 2003-03-12
RU2005127667A (ru) 2006-03-27
IS8008A (is) 2005-08-30
DE602004009288T2 (de) 2008-07-10
RU2360681C2 (ru) 2009-07-10
JP2006516602A (ja) 2006-07-06
ATE374612T1 (de) 2007-10-15
NO20053626L (no) 2005-08-26
RU2008138166A (ru) 2010-03-27
PL214680B1 (pl) 2013-09-30
TWI354556B (en) 2011-12-21
JP2011001388A (ja) 2011-01-06
CN100393360C (zh) 2008-06-11
IS2547B (is) 2009-10-15
DE602004009288D1 (de) 2007-11-15
DK1589976T3 (da) 2007-12-27
EP1857111A3 (en) 2009-03-04
ZA200506221B (en) 2006-05-31
TW200503731A (en) 2005-02-01
EP1589976A1 (en) 2005-11-02
BRPI0407039A (pt) 2006-01-17
US20110009373A1 (en) 2011-01-13
US7910570B2 (en) 2011-03-22
CA2513910C (en) 2012-04-03
PT1589976E (pt) 2007-11-22
KR101075929B1 (ko) 2011-10-26
CN1747736A (zh) 2006-03-15
EP1589976B1 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
PL1646634T3 (pl) Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości
MXPA06000123A (es) Suspension aislante de apoyo central de resorte rapido de plastico y metodo para fabricar y ensamblar el mismo.
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
MY137766A (en) Exemestane as chemopreventing agent
TW200716088A (en) Formulations and methods for treating amyloidosis
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
HK1082918A1 (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
MXPA05011501A (es) Combinacion terapeutica de un inhibidor de cox-2 y un inhibidor de aromatasa.
MY138479A (en) 7alpha-hydroxyacetyl and 7alpha-hydroperoxyacetyl-substituted steroid compounds
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
TW200512009A (en) Hair treatment compositions
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
MY140194A (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
FG Grant or registration